141 related articles for article (PubMed ID: 5040981)
41. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
Litam PP; Landaw SA; Zamkoff KW
Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
[TBL] [Abstract][Full Text] [Related]
42. Polycythemia vera and pregnancy: a case report with the use of hydroxyurea in the first trimester.
Pata O; Tok CE; Yazici G; Pata C; Oz AU; Aban M; Dilek S
Am J Perinatol; 2004 Apr; 21(3):135-7. PubMed ID: 15085495
[TBL] [Abstract][Full Text] [Related]
43. Coexistence of β-thalassemia and polycythemia vera.
Lopes da Silva R; Silva M
Blood Cells Mol Dis; 2011 Feb; 46(2):171-2. PubMed ID: 21193338
[No Abstract] [Full Text] [Related]
44. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
Boivin P
Nouv Rev Fr Hematol (1978); 1993; 35(5):491-8. PubMed ID: 8295823
[TBL] [Abstract][Full Text] [Related]
45. A case of hydroxyurea-induced longitudinal melanonychia.
Utaş S; Kulluk P
Int J Dermatol; 2010 Apr; 49(4):469-70. PubMed ID: 20465711
[No Abstract] [Full Text] [Related]
46. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
[TBL] [Abstract][Full Text] [Related]
47. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
Barosi G; Birgegard G; Finazzi G; Griesshammer M; Harrison C; Hasselbalch H; Kiladijan JJ; Lengfelder E; Mesa R; Mc Mullin MF; Passamonti F; Reilly JT; Vannucchi AM; Barbui T
Br J Haematol; 2010 Mar; 148(6):961-3. PubMed ID: 19930182
[No Abstract] [Full Text] [Related]
48. Antineutrophil cytoplasmic antibody-associated vasculitis in a patient with polycythemia vera after long-term hydroxyurea treatment.
Su L; Zheng J; Xiu L; Li J; Ding M; He W
Leuk Lymphoma; 2011 Nov; 52(11):2193-4. PubMed ID: 21718133
[No Abstract] [Full Text] [Related]
49. Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study.
Büyükaşık Y; Ali R; Turgut M; Saydam G; Yavuz AS; Ünal A; Ar MC; Ayyıldız O; Altuntaş F; Okay M; Çiftçiler R; Meletli Ö; Soyer N; Mastanzade M; Güven Z; Soysal T; Karakuş A; Yiğenoğlu TN; Uçar B; Gökçen E; Tuğlular T
Turk J Haematol; 2020 Aug; 37(3):177-185. PubMed ID: 32075363
[TBL] [Abstract][Full Text] [Related]
50. Treatment of polycythemia vera with hydroxyurea.
Sharon R; Tatarsky I; Ben-Arieh Y
Cancer; 1986 Feb; 57(4):718-20. PubMed ID: 3943010
[TBL] [Abstract][Full Text] [Related]
51. Lymphoma transformation in polycythaemia vera treated with hydroxyurea.
Hawkins TE; Carter JM; Romeril KR; Jackson SR; Green GJ
Am J Hematol; 1993 Dec; 44(4):290. PubMed ID: 8238005
[No Abstract] [Full Text] [Related]
52. Multiple actinic keratosis and skin tumors secondary to hydroxyurea treatment.
Salmon-Ehr V; Grosieux C; Potron G; Kalis B
Dermatology; 1998; 196(2):274. PubMed ID: 9568428
[No Abstract] [Full Text] [Related]
53. Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?
Spivak JL
Lancet Haematol; 2020 Mar; 7(3):e184-e185. PubMed ID: 31982040
[No Abstract] [Full Text] [Related]
54. The cutaneous side-effects of hydroxyurea.
Young HS; Khan AS; Kendra JR; Coulson IH
Clin Lab Haematol; 2000 Aug; 22(4):229-32. PubMed ID: 11012636
[TBL] [Abstract][Full Text] [Related]
55. Perimalleolar ulcers in hydroxyurea treated patients with concomitant chronic venous disease: diagnostic pitfalls.
Jain V; Gupta K; Nagpal N
J Coll Physicians Surg Pak; 2005 Oct; 15(10):658-60. PubMed ID: 19810313
[TBL] [Abstract][Full Text] [Related]
56. Early medical treatment is life saving in acute Budd-Chiari due to polycythemia vera.
Karti SS; Yilmaz M; Kosucu P; Altun E; Kesen J; Arslan M; Ozgur O; Ovali E
Hepatogastroenterology; 2003; 50(50):512-4. PubMed ID: 12749260
[TBL] [Abstract][Full Text] [Related]
57. Epstein-Barr virus-positive mucocutaneous ulcer in a patient with polycythemia vera treated with oral hydroxyurea.
Hamada T; Kawata M; Maeda Y; Yoshino T; Miyake T; Morizane S; Hirai Y; Iwatsuki K
J Dermatol; 2018 Apr; 45(4):e82-e83. PubMed ID: 29139148
[No Abstract] [Full Text] [Related]
58. [Therapy of polycythemia vera with myleran].
Krykowski E; Wislawska B; Polkowska-Kulesza E
Przegl Lek; 1965; 21(7):481-3. PubMed ID: 5848465
[No Abstract] [Full Text] [Related]
59. Cutaneous effects after prolongaded use of hydroxyurea in Polycythemia Vera.
França ER; Teixeira MA; Matias Kde F; Antunes DE; Braz Rde A; Silva CE
An Bras Dermatol; 2011; 86(4):751-4. PubMed ID: 21987143
[TBL] [Abstract][Full Text] [Related]
60. Improvement of fibrosis in a patient with chronic myeloproliferative disease.
Retter A; Radia DH; Harrison CN
Br J Haematol; 2007 Nov; 139(3):350. PubMed ID: 17910624
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
